Evidence map›Paper›PMID 35674216›Full record

ArticleFEBS open bio2022

Development of a fully human anti-GITR antibody with potent antitumor activity using H2L2 mice.

Qiuli Tong, Hu Liu, Qianqian Qi, Chaohui Dai, Teddy Yang, Feng Qian

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Qiuli TongShanghai Public Health Clinical Center, Human Phenome Institute and School of Life Sciences, Fudan University, Shanghai, China.ORCID 0000-0002-5582-6585
Hu LiuShanghai Chempartner Co., Ltd, China.
Qianqian QiShanghai Chempartner Co., Ltd, China.
Chaohui DaiShanghai PharmaExplorer Co., Ltd., China.
Teddy YangShanghai Chempartner Co., Ltd, China.
Feng QianShanghai Public Health Clinical Center, Human Phenome Institute and School of Life Sciences, Fudan University, Shanghai, China.
dataPartner (Czechia) · CZShanghai Public Health Clinical Center · CNFosun Pharma (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucocorticoid-induced TNF receptor-related (GITR) can act as a co-stimulatory receptor, representing a potential target for safely enhancing immunotherapy efficacy. GITR is triggered by a GITR ligand or an agonist antibody and activates CD8

Indexed as

GlucocorticoidsReceptors, Tumor Necrosis FactorAnimalsAntibodiesCell Line, TumorGlucocorticoid-Induced TNFR-Related ProteinHumansImmunotherapyMiceAntibodiesGlucocorticoid-Induced TNFR-Related ProteinGlucocorticoidsReceptors, Tumor Necrosis Factorengineering modificationfully human antibodyGITRH2L2 miceimmunization strategiesT cell

Identifiers

PMID35674216
PMCPMC9340783
OpenAlexW4282923907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.